NurExone Biologic Inc. a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medici...
Ontada®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, has ...
Perceptive eClinical, part of Perceptive Group, is pleased to announce the launch of ClinPhone 5, a ground-breaking new Randomization and Trial Supply Mana...
Stamford Health's Heart & Vascular Institute has announced it will be the first in Connecticut to offer a new, AI-powered cardiovas...
Professor Narayanan Parameswaran's team at the Department of Physiology at Michigan State University announced the results of a study that s...
GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site...
Moderna, Inc. (NASDAQ:MRNA) announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the ...
Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that...
Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...
The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 578 million (USD 4.0 million1) in four...
Agilent Technologies Inc. (NYSE: A) announced that Professor Isabelle Plante at Institut National de la Recherche Scientifique (INRS), and&n...
Headway, the company building a new mental healthcare system, announced its participation in the Aligned Innovation initiative, a groundbreaking cross-indu...
At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics, a pioneering genomic sequencing company, will highligh...
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...
© 2025 Biopharma Boardroom. All Rights Reserved.
